Regulatory News:

DEINOVE (Paris:ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces today its provisional financial calendar for 2020*.

  • April 2nd, 2020: Publication of 2019 Annual Results
  • June 16th, 2020: Annual Shareholders’ Meeting, in Paris (2:00pm CET)
    at Fieldfisher Law firm, 48, rue Cambon, 75001 Paris
  • October 1st, 2020: Publication of 2020 First Half Financial Results

* This financial calendar is for indicative purposes only and the Company could change its publication dates, should it deem necessary.

ABOUT DEINOVE

DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries.

DEINOVE has developed a unique and comprehensive expertise in the field of rare bacteria that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale. To do so, DEINOVE has been building and documenting since its creation an unparalleled biodiversity bank that it exploits thanks to a unique technological platform in Europe.

DEINOVE is organized around two areas of expertise:

  • ANTIBIOTICS, New-generation anti-infective drugs: A first antibiotic candidate is now in Phase II. The Company is also pursuing the systematic exploration of biodiversity to supply its portfolio with new leads, drawing notably on partnerships with bioMérieux and Naicons (AGIR program supported by Bpifrance).
  • BIOACTIVES, Active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: DEINOVE is already marketing a first cosmetic active ingredient, a second in partnership with Greentech and plans to launch new proprietary assets in 2020. Several other cosmetic actives are in development, including with Oléos (Hallstar Group) and Dow. It also runs a program in animal nutrition with Groupe Avril.

Within the Euromedecine science park located in Montpellier, DEINOVE employs 60 employees, mainly researchers, engineers, and technicians, and has filed more than 350 patent applications internationally. The Company has been listed on EURONEXT GROWTH® since April 2010.

Visit www.deinove.com